Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of JTT-251 in heart failure with reduced ejection fraction
MOH_2019-01-16_004915Phase 2Completed
- Sponsor
- Acros Organics
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JTT-251 in heart failure with reduced ejection fraction (HFrEF) (5 arms), sponsored by Acros Organics. Started Dec 2018; status: completed.
02
Drugs
JTT-251
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on MOH_2019-01-16_004915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-16_004915.